Evaluation of the performance of 25 SARS-CoV-2 serological rapid diagnostic tests using a reference panel of plasma specimens at the Uganda Virus Research Institute

Evaluation of the performance of 25 SARS-CoV-2 serological rapid diagnostic tests using a reference panel of plasma specimens at the Uganda Virus Research Institute

Introduction: Serological testing is needed to better understand the epidemiology of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Rapid diagnostic tests (RDTs) have been developed to detect specific antibodies, IgM and IgG, to the virus. The performance of 25 of these RDTs...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tom Lutalo, Aminah Nalumansi, Denis Olara, John Kayiwa, Bernard Ogwang, Emmanuel Odwilo, Christine Watera, Stephen Balinandi, Jocelyn Kiconco, Joweria Nakaseegu, Jennifer Serwanga, Bernard Kikaire, Deogratius Ssemwanga, Brendah Abiko, Christopher Nsereko, Matthew Cotten, Joshua Buule, Julius Lutwama, Robert Downing, Pontiano Kaleebu
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
COVID-19
SARS-CoV-2
Rapid diagnostic test
antibody
serological reference panel
performance
Infectious and parasitic diseases
RC109-216
Acceso en línea:https://doaj.org/article/0b0beca23d9d43df8d2c2299dac6f1d8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Introduction: Serological testing is needed to better understand the epidemiology of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Rapid diagnostic tests (RDTs) have been developed to detect specific antibodies, IgM and IgG, to the virus. The performance of 25 of these RDTs was evaluated. Methods: A serological reference panel of 50 positive and 100 negative plasma specimens was developed from SARS-CoV-2 PCR and antibody positive patients and pre-pandemic SARS-CoV-2-negative specimens collected in 2016. Test performance of the 25 RDTs was evaluated against this panel. Results: A total of 10 RDTs had a sensitivity ≥98%, while 13 RDTs had a specificity ≥98% to anti-SARS-CoV-2 IgG antibodies. Four RDTs (Boson, MultiG, Standard Q, and VivaDiag) had both sensitivity and specificity ≥98% to anti-SARS-CoV-2 IgG antibodies. Only three RDTs had a sensitivity ≥98%, while 10 RDTs had a specificity ≥98% to anti-SARS-CoV-2 IgM antibodies. Three RDTs (Autobio, MultiG, and Standard Q) had sensitivity and specificity ≥98% to combined IgG/IgM. The RDTs that performed well also had perfect or almost perfect inter-reader agreement. Conclusions: This evaluation identified three RDTs with a sensitivity and specificity to IgM/IgG antibodies of ≥98% with the potential for widespread antibody testing in Uganda.

Ejemplares similares